Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared a post on Linkedin:
“New post: Granulocyte Transfusions for the Overworked Fellow.
Someone suggests granulocytes for your profoundly neutropenic, fungal-infected, not-responding patient. You nod. You place the consult. And somewhere in the back of your mind, a small voice asks: does this actually work?
That voice deserves an honest answer.
Here’s what the literature actually gives us:
- The biological rationale is sound. No neutrophils, no innate immune response. Supplementing from the outside makes mechanistic sense.
- The RING trial was the most rigorous attempt to test this — randomized, adequately powered, mortality endpoint. It didn’t show a survival benefit.
- But RING had a problem: delivered doses were consistently below what’s considered therapeutic. If you can’t reliably deliver the intervention, you can’t cleanly interpret the result.
- The amphotericin timing rule? Traced back to a single 1981 paper. Subsequent studies failed to replicate it. The practice outlived the evidence.
- The 1 × 10¹⁰ dose target is real — but collection yields are variable, and hitting it is not guaranteed even with G-CSF and dexamethasone stimulation.
We have not arrived at a definitive answer on whether granulocyte transfusions improve survival. We tried hard to find out. The best trial we have had a fatal flaw in its ability to deliver the intervention reliably.
Knowing the limits of the evidence is not a failure of clinical knowledge. It is the clinical knowledge.”

Other posts featuring Caitlin Raymond on Hemostasis Today.
-
May 28, 2026, 14:21Abdul Mannan: The Hidden Role of Factor XIII in Protecting Clot Stability
-
May 28, 2026, 14:14Spelile Mutupira: Why Hemolysis Remains a Major Laboratory Challenge
-
May 28, 2026, 14:08Fredrick Chalinga: The Science Behind Blood Group Immunogenicity
-
May 28, 2026, 14:00Kalyan Roy: The Critical Role of Chelation Therapy in Thalassaemia
-
May 28, 2026, 13:42Claudio Laudani: Balancing Ischemic and Bleeding Risk in AF with Coronary Disease
-
May 28, 2026, 13:30When it Comes to Stroke Care, Quality Matters – Duke Health
-
May 28, 2026, 13:29Natalie Johnson: Transforming PE Care Through Endovascular Innovation
-
May 28, 2026, 13:16Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients
-
May 28, 2026, 12:57Ahmed Kardousha: Protecting Growth and Fertility in Transfusion-Dependent β-Thalassemia